Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Anemia

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 32 articles:
HTML format



Single Articles


    January 2024
  1. HARRIS E
    Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
    JAMA. 2024;331:280.
    PubMed    


    October 2023
  2. SIEGAL DM, Belley-Cote EP, Lee SF, Hill S, et al
    Small-Volume Blood Collection Tubes to Reduce Transfusions in Intensive Care: The STRATUS Randomized Clinical Trial.
    JAMA. 2023 Oct 12. doi: 10.1001/jama.2023.20820.
    PubMed     Abstract available


  3. RAASVELD SJ, de Bruin S, Reuland MC, van den Oord C, et al
    Red Blood Cell Transfusion in the Intensive Care Unit.
    JAMA. 2023 Oct 12. doi: 10.1001/jama.2023.20737.
    PubMed     Abstract available


  4. HARRIS E
    Stem Cell Gene Editing Improved Sickle Cell Disease Outcomes.
    JAMA. 2023;330:1218.
    PubMed    


    June 2023
  5. HARRIS E
    Daily Dose of Aspirin Linked With Anemia in Older People.
    JAMA. 2023 Jun 28. doi: 10.1001/jama.2023.11954.
    PubMed    


  6. WEYAND AC, Chaitoff A, Freed GL, Sholzberg M, et al
    Prevalence of Iron Deficiency and Iron-Deficiency Anemia in US Females Aged 12-21 Years, 2003-2020.
    JAMA. 2023;329:2191-2193.
    PubMed    


    February 2023
  7. HARRIS E
    FDA Approves First Oral Treatment for Kidney Disease-Induced Anemia.
    JAMA. 2023 Feb 15. doi: 10.1001/jama.2023.1556.
    PubMed    


  8. LARKIN HD
    Sickle Cell Disease Gene Therapy Trial Paused.
    JAMA. 2023;329:364.
    PubMed    


    November 2022
  9. VLACHADIS N, Vrachnis N
    A Review of Sickle Cell Disease.
    JAMA. 2022;328:1979.
    PubMed    


  10. KAVANAGH PL, Fasipe T, Wun T
    A Review of Sickle Cell Disease-Reply.
    JAMA. 2022;328:1979-1980.
    PubMed    


  11. LARKIN HD
    Gene Therapy for Sickle Cell Disease, beta-Thalassemia Enters Regulatory Reviews.
    JAMA. 2022;328:1798.
    PubMed    


    October 2022
  12. KUEHN BM
    Children With Sickle Cell Anemia Not Receiving Recommended Care.
    JAMA. 2022;328:1583-1584.
    PubMed    


    September 2022
  13. RUBIN R
    New Gene Therapy for beta-Thalassemia.
    JAMA. 2022;328:1030.
    PubMed    


    August 2022
  14. SLOMSKI A
    Sickle Cell Trait Associated With Kidney Failure and COVID-19 Death.
    JAMA. 2022;328:415.
    PubMed    


    July 2022
  15. KAVANAGH PL, Fasipe TA, Wun T
    Sickle Cell Disease: A Review.
    JAMA. 2022;328:57-68.
    PubMed     Abstract available


    June 2022
  16. OSHIMA T, Kinjo K, Kinjo M
    Chronic Abdominal Pain and Anemia in a 59-Year-Old Man.
    JAMA. 2022 Jun 24. pii: 2793812. doi: 10.1001/jama.2022.9194.
    PubMed    


    February 2022
  17. SLOMSKI A
    Oral Daprodustat Treats Anemia in Chronic Kidney Disease.
    JAMA. 2022;327:710.
    PubMed    


    October 2021
  18. ABOU BAKER NM, Davis AM
    Gastrointestinal Evaluation of Iron Deficiency Anemia.
    JAMA. 2021;326:1624-1625.
    PubMed    


    September 2021
  19. KENTER MJH, Cohen AF
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    JAMA. 2021;326:974-975.
    PubMed    


  20. GURKAN UA
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    JAMA. 2021;326:975.
    PubMed    


  21. CASELLA JF, Kronsberg SS, Gorney RT
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply.
    JAMA. 2021;326:975-976.
    PubMed    


    July 2021
  22. ZHANG H, Kilaru AS, Meisel ZF, Bao Y, et al
    Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients With Sickle Cell Disease or Cancer With Bone Metastasis.
    JAMA. 2021;326:274-276.
    PubMed    


    June 2021
  23. SATO T, Terada R, Ikeda T
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia.
    JAMA. 2021;325:2505-2506.
    PubMed    


  24. DUCROCQ G, Simon T, Steg PG
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia-Reply.
    JAMA. 2021;325:2506-2507.
    PubMed    


    May 2021

  25. Foreign Letters: London.
    JAMA. 2021;325:1907.
    PubMed    


    April 2021
  26. ZYLKE J
    Poloxamer 188 for Sickle Cell Disease.
    JAMA. 2021;325:1524.
    PubMed    


  27. CASELLA JF, Barton BA, Kanter J, Black LV, et al
    Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
    JAMA. 2021;325:1513-1523.
    PubMed     Abstract available


  28. EHRENREICH H, Neubauer AP, Miskowiak K
    Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years.
    JAMA. 2021;325:1470-1471.
    PubMed    


  29. NATALUCCI G, Bucher HU, Fauchere JC
    Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years-Reply.
    JAMA. 2021;325:1471-1472.
    PubMed    


    February 2021
  30. DUCROCQ G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, et al
    Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.
    JAMA. 2021;325:552-560.
    PubMed     Abstract available


    January 2021
  31. ABBASI J
    Promising Strategies for Sickle Cell Disease and beta-Thalassemia.
    JAMA. 2021;325:121.
    PubMed    


    December 2020
  32. NATALUCCI G, Latal B, Koller B, Ruegger C, et al
    Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.
    JAMA. 2020;324:2324-2327.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Anemia is free of charge.